This idea was also supported by a previous work by Jimeno et al.: by profiling xenografted pancreatic cancers treated with the EGFR inhibitor erlotinib, they proposed a molecular signature for sensitivity to EGFR inhibitor involving core components of the EGFR pathway [85]. This evidence concerns the gene EGFR and pancreatic neoplasm.